StockData

BioCryst Pharmaceuticals vs Tarsus Pharmaceuticals

BCRX and TARS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCRX and TARS compare

Tarsus Pharmaceuticals is the larger company, worth 1.8 times as much as BioCryst Pharmaceuticals ($3.4B against $1.9B).

Tarsus Pharmaceuticals grew revenue faster over the last twelve months (105% versus 68.7% for BioCryst Pharmaceuticals).

Tarsus Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −7.7% compared with −40.9% at BioCryst Pharmaceuticals.

Tarsus Pharmaceuticals scores higher on the StockData Score (10 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCRXTARS
Size and price
Market cap$1.9B$3.4B
Share price$7.50$78.20
Change, 1 year5.9%7.2%
Change, 5 years−39.9%213%
Beta (5Y)0.580.85
Employees435370
StockData Score
Total score910 (better)
Valuation score1 (better)0
Growth score4 (better)3
Performance score23 (better)
Health score24 (better)
Dividend score00
Valuation
P/S2.0× (better)5.7×
P/B–9.9×
P/FCF5.1× (better)61.3×
FCF yield19.5% (better)1.6%
Fair value–$75.18
Margin of safety–−4.0%
Growth
Revenue growth (TTM)68.7%105% (better)
Revenue growth, 5Y average118%–
Profitability
Gross margin97.8%–
Operating margin−33.3%−8.0% (better)
Net margin−40.9%−7.7% (better)
FCF margin39.7% (better)9.2%
Return on equity–−13.7%
Financial health
Debt / equity–0.21
Interest coverage−4.2× (better)−5.5×
Current ratio2.323.20 (better)
Altman Z-score−3.838.24 (better)
Piotroski F-score7 (better)4
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions103%110%
Held by insiders1.9%3.1%
Insider net buying, 12 months−$4.1M (better)−$20.0M
Short interest, % of float11.0%14.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.